Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors

Michela Casanova, Maura Massimino, Andrea Ferrari, Filippo Spreafico, Luigi Piva, Jorgelina Coppa, Roberto Luksch, Graziella Cefalo, Monica Terenziani, Daniela Polastri, Franca Fossati Bellani, Vincenzo Mazzaferro

Research output: Contribution to journalArticlepeer-review


To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalPediatric Hematology and Oncology
Issue number3
Publication statusPublished - Apr 2005


  • Chemotherapy
  • Cis platin
  • Epirubicin
  • Etoposide
  • Hepatoblastoma
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors'. Together they form a unique fingerprint.

Cite this